StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Autolus Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Autolus Therapeutics's price to book ratio was 4.4× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.6× to 10.0×, with a median of 1.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.4×+2.4
2025Dec 31, 20252.0×+0.9
2024Dec 31, 20241.1×−4.5
2023Dec 29, 20235.6×+4.8
2022Dec 30, 20220.8×−0.1
2021Dec 31, 20210.9×−0.2
2020Dec 31, 20201.2×−0.4
2019Dec 31, 20191.6×−2.4
2018Dec 31, 20184.1×–

More Autolus Therapeutics figures

See a number that looks wrong?